Cover Image
Market Research Report

Company Profile: Novo Nordisk

Published by Datamonitor Healthcare Product code 603959
Published Content info 36 Pages
Delivery time: 1-2 business days
Back to Top
Company Profile: Novo Nordisk
Published: December 13, 2017 Content info: 36 Pages

Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores Amgen's prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-26.


  • Overview - Novo Nordisk continues to dominate the diabetes segment, with approvals of the next-generation insulin FIAsp (ultra fast-acting insulin aspart) and the GLP-1 agonist Ozempic (semaglutide) set to further boost sales.
  • Out to 2021 - Novo Nordisk will experience headwinds, especially in the US, as pricing pressure results in steadily declining diabetes sales.
  • Out to 2026 - Novo Nordisk is likely to look for alternative therapy segments to source long-term growth as the diabetes market becomes increasingly crowded.
  • Pipeline - The highly anticipated oral semaglutide is in Phase III trials, while hemophilia treatment N8-GP is set for approval in 2018.
  • Events - Novo Nordisk gained US Food and Drug Administration approval for GLP-1 agonist Ozempic in December 2017, with product launch expected on 1 January 2017.


  • Q3 2017: Novo Nordisk's Q3 2017 sales are up by 2%.
  • Despite headwinds in the US diabetes market, Novo Nordisk will continue to dominate the global metabolic market.
  • Novo Nordisk's hematology segment will contribute a comparatively modest proportion of total sales, despite approval of new medicines over the forecast period.

Model updates:

  • N9-GP updated to Rebinyn.
  • Oral semaglutide (NN9924) added.
  • Saxenda added.
  • Semaglutide changed to Ozempic.

Analysis structure:

  • Explore and visualize revenue dynamics in Amgen's portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.

Company context:

  • How is Novo Nordisk strategically poised out to 2026?
  • What are Novo Nordisk's key strengths, weaknesses, opportunities, and threats?
  • What are Novo Nordisk's key catalysts during the current year?

Facts and figures:

  • What is Novo Nordisk's forecasted sales performance out to 2026?
  • What is the revenue trajectory of Novo Nordisk's current top 10 products out to 2026?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Novo Nordisk based on the lifecycle of its products?

Key therapy areas:

  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Novo Nordisk's important therapeutic markets?
  • How is Novo Nordisk adapting strategically to internal and external headwinds?
Table of Contents
Product Code: DMKC0134576



Q3 2017 REVIEW

  • Novo Nordisk outlook
  • What were the highlights of Novo Nordisk's Q3 earnings report?
  • Pipeline events
  • Novo Nordisk 9 month 2017 sales


  • Novo Nordisk is the largest developer of diabetes products the world
  • Novo Nordisk pins outlook on GLP-1 portfolio
  • Novo Nordisk faces intensified pricing pressure in the US
  • Novo Nordisk looks to M&A to secure future growth
  • Novo Nordisk's SWOT analysis
  • Upcoming catalysts


  • Novo Nordisk's prescription pharma sales outlook
  • Novo Nordisk's therapy area dynamics
  • Novo Nordisk's top products over 2016-26
  • Novo Nordisk's growth drivers and resistors
  • Novo Nordisk's launch/core/expiry analysis
  • Novo Nordisk's financial outlook
  • Novo Nordisk's M&A history


  • Metabolic
  • Hematology



  • Figure 1: Novo Nordisk's prescription pharmaceutical sales ($m) and growth rate (%), 2013-26
  • Figure 2: Novo Nordisk's therapy area dynamics, 2016-26
  • Figure 3: Novo Nordisk's top product sales ($m), 2016-26
  • Figure 4: Novo Nordisk's launch/core/expiry portfolio configuration, 2016-26
  • Figure 5: Novo Nordisk's operating revenue/cost analysis ($m), 2009-21


  • Table 1: Novo Nordisk 9 month 2017 sales
  • Table 2: Novo Nordisk potential M&A targets
  • Table 3: Novo Nordisk's sales by therapy area ($m), 2016-26
  • Table 4: Novo Nordisk's key products, 2016-26
  • Table 5: Novo Nordisk's sales by launch, core, and expiry portfolio ($m), 2016-26
  • Table 6: Novo Nordisk's financial performance, 2015-21
  • Table 7: Novo Nordisk's key merger and acquisition deals, 2002-16
  • Table 8: Novo Nordisk's metabolic portfolio sales, by product ($m), 2016-26
  • Table 9: Novo Nordisk's hematology portfolio sales, by product ($m), 2016-26
Back to Top